Recent spectacular advances in biotechnology--site directed mutagenesis, monoclonal antibodies, semi-synthetic enzymes, membrane reactors and others--are rapidly providing new and powerful forms of catalysis. Our research group is investigating how to integrate this new technology with classical organic chemistry to synthesize materials for biology and medicine. Specific goals are: 1) to develop readily available proteins as catalysts for use in natural product synthesis 2) to engineer new proteins through the use of mutagenesis; 3) to develop proteins for synthetic transformations that are difficult or impossible to perform using classical organic chemistry. Natural products serve as a goal to develop new synthetic methodology. We are pursuing the stereoselective synthesis of unusual peptides such as statine, the construction of antitumor agents (adriamycin and daunorubicin), the synthesis of glycosidase inhibitors (castanospermine and norjirimyucin) and the synthesis of noel alkaloids (gephrotoxin) to develop the use of enzyumes in organic synthesis. To effectively use enzymes for synthetic chemistry, methods are also being developed to use proteins in organic solvents and alter their substrated specificity either through chemical or genetic techniques. We are pursuing both approaches. Our group, for example, is using mutagenesis to change the substrate specificity of carbon-carbon bond forming enzymes. Mutations are made on DNA which codes for an aldolase protein and the altered gene spliced into a plasmid which is transformed into E. coli. These mutants are forced to accept unnatural (synthetic) substrates by coupling the occurence of the desired catalytic process with the release of material which is necessary for the survival of the organism. All relevant enzymes are designed for synthetic applications, that is to stereoselectively form key bonds in the construction of natural products. The development of methods in biotechnology to execute stereoselective organic transformations is important for the development of new safe and economical methods in organic chemistry.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29GM043037-04
Application #
3467865
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Project Start
1989-07-01
Project End
1993-06-30
Budget Start
1992-07-01
Budget End
1993-06-30
Support Year
4
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of California Berkeley
Department
Type
Schools of Arts and Sciences
DUNS #
094878337
City
Berkeley
State
CA
Country
United States
Zip Code
94704